Oncocyte Corporation (OCX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome, everyone, and thank you for joining us to discuss OncoSight's first quarter 2025 results. If you have not seen today's shareholder letter, please visit OncoSight's investor relations page at investors.oncosight.com. Today's prepared remarks build upon the information already shared in this robust letter. Joining us today are OncoSight President and CEO Josh Riggs, Chief Science Officer Eki Schutz, and CFO Andrea James. We also have our analysts with us as panelists. After our prepared remarks, our analysts may ask questions. Before turning the call over to Josh Riggs, I'd like to go over our safe harbor. The company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts are forward-looking statements. These statements are made pursuant to and within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. We encourage you to review the company's SEC filings, including the company's most recent form 10-K and subsequent forms 10-Q, which identify risks and uncertainties that may cause future actual results or events to differ materially. On this note, but the forward-looking statements made during today's call speak only to the date that they are made and Oncocyte undertakes no obligation to update them. And with that, I would like to now turn the call over to Josh Riggs. Hi, everyone. Thanks for joining us today. It's great to be checking in with you about two months after we reported our annual results. We've been heads down executing on our 2025 plan. For those of you who are new to us, we're a molecular diagnostics company investing in the significant opportunity to improve transplant rejection testing. We are just over two years into a strategic pi...